| A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease |
42 |
| Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis |
37 |
| Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib |
34 |
| Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1 |
31 |
| Increased Risk of Influenza and Influenza-Related Complications Among 480 Patients With Inflammatory Bowel Disease |
30 |
| Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I |
28 |
| The Artificial Sweetener Splenda Promotes Gut Proteobacteria, Dysbiosis, and Myeloperoxidase Reactivity in Crohn's Disease-Like Ileitis |
27 |
| Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases |
24 |
| Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis |
24 |
| Inflammatory Bowel Disease and Parkinson's Disease: A Nationwide Swedish Cohort Study |
22 |
| Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention |
22 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis |
21 |
| Sarcopenia and Inflammatory Bowel Disease: A Systematic Review |
21 |
| Nanoparticle-Based Oral Drug Delivery Systems Targeting the Colon for Treatment of Ulcerative Colitis |
19 |
| The Mesenteric Fat and Intestinal Muscle Interface: Creeping Fat Influencing Stricture Formation in Crohn's Disease |
18 |
| Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease |
18 |
| Systematic Review and Meta-analysis: Vedolizumab and Postoperative Complications in Inflammatory Bowel Disease |
16 |
| Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting |
16 |
| Determinants of IBD Heritability: Genes, Bugs, and More |
16 |
| Mitochondrial DNA Is a Pro-Inflammatory Damage-Associated Molecular Pattern Released During Active IBD |
15 |
| Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells' Differentiation and Function in Induction of Colitis |
15 |
| Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD |
15 |
| Safety, Clinical Response, and Microbiome Findings Following Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease |
15 |
| Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity? |
15 |
| Bacteroides thetaiotaomicron Ameliorates Colon Inflammation in Preclinical Models of Crohn's Disease |
14 |
| Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience |
14 |
| Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis |
13 |
| Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part II |
13 |
| Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy |
13 |
| The Influence of Hormonal Fluctuation on Inflammatory Bowel Disease Symptom Severity-A Cross-Sectional Cohort Study |
13 |
| Eosinophils in Inflammatory Bowel Disease |
12 |
| Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis |
12 |
| Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease |
12 |
| Long ncRNA Landscape in the Ileum of Treatment-Naive Early-Onset Crohn Disease |
12 |
| Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis |
12 |
| Antibiotics in IBD: Still a Role in the Biological Era? |
12 |
| A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD |
12 |
| Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort |
12 |
| Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study |
12 |
| Dietary Interventions to Modulate the Gut Microbiome-How Far Away Are We From Precision Medicine |
11 |
| Ancient Nuclear Receptor VDR With New Functions: Microbiome and Inflammation |
11 |
| The Role of Early Biologic Therapy in Inflammatory Bowel Disease |
11 |
| The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis |
11 |
| Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography |
11 |
| Inflammation and Inflammatory Cytokine Contribute to the Initiation and Development of Ulcerative Colitis and Its Associated Cancer |
11 |
| Management of Pouchitis and Other Common Complications of the Pouch |
11 |
| The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease |
11 |
| Risk of Myocardial Infarction in Inflammatory Bowel Disease: A Population-based National Study |
10 |
| Differential Susceptibility to T Cell-Induced Colitis in Mice: Role of the Intestinal Microbiota |
10 |
| Helicobacter pylori Colonization Protects Against Chronic Experimental Colitis by Regulating Th17/Treg Balance |
10 |
